Ironwood Pharmaceuticals | IRWD - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Almirall EUR 30.23M 12.8M 2025-12
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amarin USD -2.26M 564K 2025-12
Ardelyx USD 5.1M 431K 2025-12
Astellas Pharma JPY 48.57B 85.97B 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Charles River Laboratories USD 119.9M 44.08M 2026-03
Coherus Biosciences USD -39.08M 3.65M 2025-12
Emergent BioSolutions USD -218M 69.9M 2023-06
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Moderna USD -1.39B 531M 2026-03
Myriad Genetics USD -3M 20.3M 2025-12
Pacira USD 4.62M 1.43M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Takeda JPY -13.62B 182.44B 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12